AKRO - Eli Lilly beats in Q4 as obesity drug sales blow past estimates
2024-02-06 07:25:47 ET
More on Eli Lilly
- Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
- Biotech And Pharma Diversification Pays Off
- Eli Lilly: The Cupboard Is Fully Stocked
- Eli Lilly beats top-line and bottom-line estimates; initiates FY24 outlook
- Eli Lilly Q4 results to highlight Zepbound uptake